Coherus BioSciences, Inc. (CHRS) financial statements (2022 and earlier)

Company profile

Business Address C/O DENNIS M. LANFEAR
REDWOOD CITY, CA 94065
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:41754117872127125158
Cash and cash equivalents41754117872127125158
Other undisclosed cash, cash equivalents, and short-term investments 0     
Restricted cash and investments   0000
Receivables123157142 122
Inventory, net of allowances, customer advances and progress billings3844102   
Inventory3844102   
Prepaid expense   2183235
Other current assets   0033
Other undisclosed current assets2425148(1)  
Total current assets:60276734384145161197
Noncurrent Assets
Inventory, Noncurrent5648454   
Finance lease, right-of-use asset 1 
Operating lease, right-of-use asset 1011
Property, plant and equipment8 67131111
Intangible assets, net (including goodwill)4444444
Goodwill1111111
Intangible assets, net (excluding goodwill)3333333
Restricted cash and investments 001111
Other noncurrent assets10200020
Other undisclosed noncurrent assets 9     
Total noncurrent assets:77746615171715
TOTAL ASSETS:67984240999163178212
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities86606233254850
Accounts payable16152615152026
Accrued liabilities482317792824
Employee-related liabilities22221811   
Debt112    
Business combination, contingent consideration, liability    361
Deferred revenue and credits 150
Other liabilities 420000
Other undisclosed current liabilities788149 025
Total current liabilities:165146115332856106
Noncurrent Liabilities
Long-term debt and lease obligation388387162777675 
Long-term debt, excluding current maturities381377152777675 
Finance lease, liability01 
Operating lease, liability7910
Liabilities, other than long-term debt28282627272847
Deferred revenue and credits 145
Due to related parties272726262525 
Other liabilities11 2222
Business combination, contingent consideration, liability 000   
Other undisclosed noncurrent liabilities      66
Total noncurrent liabilities:416415189105104103113
Total liabilities:582561304138132159219
Stockholders' equity
Stockholders' equity attributable to parent98281105(39)3221(6)
Common stock0000000
Additional paid in capital1,1481,0441,001947808558404
Accumulated other comprehensive loss(0)(0)(1)(0)(1)(1)(0)
Accumulated deficit(1,050)(763)(895)(985)(775)(537)(410)
Stockholders' equity attributable to noncontrolling interest    (1)(1)(1)
Total stockholders' equity:98281105(39)3119(7)
TOTAL LIABILITIES AND EQUITY:67984240999163178212

Income statement (P&L) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues327476356 219030
Revenue, net219030
Cost of revenue
(Cost of Goods and Services Sold)
(58)(38)(0)    
Gross profit:269438356 219030
Operating expenses(533)(282)(248)(204)(234)(306)(249)
Other undisclosed operating income  0    
Operating income (loss):(264)156108(204)(232)(116)(219)
Nonoperating income (expense)(0)1353(4)(5)
Investment income, nonoperating 1     
Foreign currency transaction gain (loss), before tax (0)0    
Other nonoperating income (expense)(0)1353(4)(5)
Interest and debt expense(23)(21)(18)(10)(10)(8)(0)
Other undisclosed loss from continuing operations before equity method investments, income taxes (0)(0)    
Income (loss) from continuing operations before equity method investments, income taxes:(287)13693(209)(238)(128)(224)
Other undisclosed income from continuing operations before income taxes  0    
Income (loss) from continuing operations before income taxes:(287)13693(209)(238)(128)(224)
Income tax expense (3)(3)    
Net income (loss):(287)13290(209)(238)(128)(224)
Net income attributable to noncontrolling interest   0001
Net income (loss) available to common stockholders, diluted:(287)13290(209)(238)(127)(223)

Comprehensive Income ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net income (loss):(287)13290(209)(238)(128)(224)
Other undisclosed comprehensive income (loss) 0(0)0(0)(0)0
Comprehensive income (loss):(287)13390(209)(238)(128)(224)
Comprehensive income, net of tax, attributable to noncontrolling interest   0001
Comprehensive income (loss), net of tax, attributable to parent:(287)13390(209)(238)(128)(223)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: